Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours (Q36641188)

15 August 2017

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours (English)

1 reference

15 August 2017

1 reference

Thomson AH

1

1 reference

15 August 2017

Vasey PA

2

1 reference

15 August 2017

Murray LS

3

1 reference

15 August 2017

Cassidy J

4

1 reference

15 August 2017

Fraier D

5

1 reference

15 August 2017

Frigerio E

6

1 reference

15 August 2017

Twelves C

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

81

1 reference

15 August 2017

99-107

1 reference

15 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690657

15 August 2017

0 references

cites work

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

Estimating impossible curves using NONMEM.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

Population pharmacokinetics of total and unbound etoposide.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374352

Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters

20 September 2018

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer

1 reference

12 December 2020

A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by r

1 reference

12 December 2020

Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry

1 reference

12 December 2020

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

12 December 2020

Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Population Pharmacokinetics and Pharmacodynamics: An Underutilized Resource

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690657

7 January 2021

Identifiers

DOI

10.1038/SJ.BJC.6690657

1 reference

15 August 2017

1 reference

15 August 2017

1 reference